EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Platform · Ways into the Engine Proposed pipeline Regulation Primary sources

Three ways into one Ingredient Engine

EUTECNIQ has one development model: the Ingredient Engine, an intake screen followed by eight stages. A program enters it one of three ways: Discover new botanicals, compounds and technologies; Develop an existing ingredient, delivery system or process; or Qualify & Supply ingredients from international manufacturers. Every program passes the intake screen first and the same four named decision gates later, and what each gate requires depends on the product category. The overview below shows the gates and the stage map; the fifteen detailed steps, filed under the eight stages, open on request, and each names the question it answers, the standards that apply, the record it leaves and who would do the work.

3 · 1 · 8Three proposed ways in, one intake screen and eight Engine stages
4botanical drugs approved under an NDA or BLA, 2006–2023
75 daysminimum between an NDI notification and marketing (21 CFR 190.6)
€700,000one OECD 451 carcinogenicity study, EU quote 2010–2018

FDA CDER, “What is a Botanical Drug?” (updated September 3, 2026); FDA authors, Ther Innov Regul Sci 2025; 21 CFR 190.6; Meigs et al., ALTEX 2018;35:275–305, Table 3.

Status. EUTECNIQ is a company in formation (what exists today): no laboratory, hired staff, customers, data, patents or results. Every EUTECNIQ step on this page is a proposal; standards, costs and base rates are from the cited sources.

Ways in and gates Proposed

Three ways in, one intake screen, four named gates

The tracks differ in where they enter the Engine, not in what they must prove. Every program first passes the intake screen (Stage 0), which names the intended use and checks that a lawful route exists whose evidence the product can pay for.

  • Discover new botanicals, compounds and technologies. It enters at Stage 1 with a new candidate (steps 1–2), and traditional use is one possible starting evidence for it, not a requirement for every program. What changes for Discover at each gate
  • Develop an existing ingredient, delivery system or process. It enters at Stage 3 or Stage 5 (step 5 or 6) with an ingredient that already has a specification. What changes for Develop at each gate
  • Qualify & Supply ingredients from international manufacturers. It enters at Stage 2, supplier qualification and identity (step 3). What changes for Qualify & Supply at each gate

Every track names its intended use first, because the use decides the category, the safety evidence worth producing and the document that closes the work.

What every track must show at each gate

The four named gates: the Engine stage each closes and its detailed steps, what every track must show, and the documented output
GateClosesEvery track must showDocumented output
Identity gateStage 4 (steps 7–8); draws on steps 3 and 5The identity method works on real lots, the content can be held within a defined range from lot to lot, and every specification has a scientifically valid method.Specification and COA package: the specification with a reason for each limit, validated methods and lot certificates of analysis
Safety gateStage 6 (steps 9, 10 and 12); draws on steps 6 and 11Safety studies are chosen for each ingredient from its known hazards, prior human use, intended intake and regulatory route, and an intake limit is set from a NOAEL or benchmark dose. No hazard is known at the intended exposure, and the estimated daily intake does not exceed the acceptable intake.Safety and exposure assessment: estimated daily intake, the safety calculation and an intake limit, with study reports where studies were run
Route gateStage 8 (steps 13–14 and 15), before any public step; first screened at Stage 0A lawful route exists for the intended use, and the evidence it needs can be produced at an acceptable cost. Counsel reviews the conclusion where the question is legal.The route’s premarket document, where it has one, drafted for the client or its counsel to sign and submit (see the category table)
Scale gateStage 7 (transfer and supply terms); draws on step 4 for commercial importsLots made at commercial scale meet the specification, imported lots clear entry, and the terms of transfer or supply are written. A change in process or composition returns to the route gate.Transfer package or supply agreement: a process development and transfer package, or supply and quality agreements with a specification exhibit and change control

What changes by track

Show one track

Choose a track to see where it starts and what changes at each gate.

Where each entry track starts and what changes for it at each gate
StepDiscover: new botanicals, compounds and technologiesDevelop: an existing ingredient, delivery system or processQualify & Supply: ingredients from international manufacturers
StartSteps 1–2. A candidate botanical, compound or technology and its starting evidence: documented traditional use, the scientific literature or a compound already described. The actives are then traced by bioactivity-guided fractionation and dereplication.An ingredient, delivery system or process that already exists and has a specification. Work starts from that specification and a measured limitation; application and delivery work is done only where a measured limitation justifies it.Supplier qualification (step 3): questionnaire, mutual NDA, desk review of process, specifications, certificates of analysis and FDA import alerts and refusals, then an on-site audit and development samples. Development work starts only if species, plant part and process are disclosed and no critical audit finding is open.
Identity gateMarkers are drawn from the actives found at step 2, then a process and a specification are built for a new ingredient (step 5).The changed ingredient is specified again and compared with the current one in a comparability package. A change in process or composition can change regulatory status, so it also reopens the route gate.Identity is confirmed on several lots with orthogonal methods, and independent results are compared with the supplier’s certificates. A certificate is relied on for other specifications only after that confirmation (21 CFR 111.75(a)(2)).
Safety gateStudies are chosen from the hazards found and the prior human use documented at step 1, and run at partner GLP laboratories where they are needed.The existing safety case is checked again: a new format can change exposure and the safety case (step 11). For a nanoscale form, FDA states that data on the conventional form alone are unlikely to address its safety.A safety evidence summary with its gaps, from the safety literature, exposure and interaction review. Development proceeds only if no hazard is known at the intended exposure.
Route gateIf a strong therapeutic signal appears, the drug path is weighed (step 15). The first lawful use fixes supplement or drug status (21 U.S.C. 321(ff)(3)(B)), so the intended category named at the start is confirmed here before any public step.The current route conclusion is reopened. A new solvent or concentration step can change composition enough to raise the question whether an extract is a new dietary ingredient.The intended U.S. use and claims are fixed: new-dietary-ingredient status for supplement use, GRAS status at the use level for food use, and importer roles under FSVP and prior notice. Other target markets are checked separately.
Scale gateThe process moves from laboratory to pilot (step 5) and into a transfer package. A drug candidate goes to a spin-off, licensee or buyer with a partnering file (step 15).The changed process or format is transferred to the site that will make it, with a transfer protocol and acceptance criteria. Process validation stays with that site.Importer roles are agreed; prior notice, customs entry, receipt testing and release follow. A supply agreement then sets the specification exhibit, change notification and audit rights, renewed on measured performance.

What changes by category

The gates are shared; the rules behind them follow the product category, which intended use and claims decide. Detail and status: regulatory routes, NDI notifications, GRAS, cosmetics and global ingredients.

What each gate requires in each U.S. product category
GateDietary supplementConventional foodCosmeticDrug
Identity gateA specification for each component, and an identity test of every dietary ingredient before use (21 CFR 111.70(b), 111.75(a)(1))21 CFR Part 117, with a supply-chain program where a supplier controls a hazard (§ 117.405)No cosmetic GMP rule has been proposed; FDA has draft guidance onlyDrug CGMP, 21 CFR Parts 210 and 211
Safety gateNo test battery is prescribed for a new dietary ingredient; FDA’s NDI guidance divides a NOAEL by a safety factor, and an EDI/ADI of 1 or less supports safetyGRAS needs the same quantity and quality of evidence as a food additive (21 CFR 170.30(b)); FDA’s Redbook table recommends the tests“Neither the law nor FDA regulations require specific tests”; qualified experts judge the safety substantiationNonclinical studies sized to each clinical trial (ICH M3(R2)), under good laboratory practice (21 CFR Part 58)
Route gateNDI notification at least 75 days before marketing, unless the food-supply exception applies (21 CFR 190.6); not an approvalA GRAS conclusion, kept or notified, or a food additive petition that FDA decides by regulation (21 CFR 170.30, 171.1); mandatory GRAS notices proposed August 11, 2026Safety substantiation records, facility registration and product listing under MoCRA (FD&C Act §§ 607–608); no FDA approval except for color additivesAn IND before clinical studies (21 CFR Part 312), then an NDA and FDA approval before marketing; partner-led
Scale gateFor an imported botanical: food facility registration, prior notice and FSVP (21 CFR 1.225 et seq.; 1.276–1.285; 1.500–1.514); the buyer still tests identity on receiptAs for supplements: food facility registration, prior notice and FSVP for an imported botanicalFacility registration under MoCRA, renewed every two yearsManufacture under Parts 210 and 211 by pharmaceutical partners; EUTECNIQ’s proposed role is characterization and partnering, not drug manufacture

Track starts and gate criteria are EUTECNIQ proposals, restating the step table below and the global-ingredient pathway. Category rules: 21 CFR 111.70, 111.75, 117.405, 170.30, 171.1, 190.6, Parts 58, 210, 211 and 312, and 1.225 et seq., 1.276–1.285 and 1.500–1.514 (eCFR, current to October 21, 2026); FD&C Act §§ 607–608; ICH M3(R2); FDA Redbook summary table (2006); FDA, “FDA Authority Over Cosmetics” (November 18, 2025); FDA NDI guidance (October 2026); 91 FR 51834 (proposed rule, August 11, 2026). Summaries as of October 31, 2026; not legal advice.

Three ways in, one intake screen, four named gatesSchematic · content from this page
Stage strip from Stage 0 to Stage 8. Discover enters at Stage 1, Qualify and Supply at Stage 2, Develop at Stage 3 or 5. Gates: identity closes Stage 4, safety closes Stage 6, scale closes Stage 7, route closes Stage 8 and is first screened at Stage 0.
Stages, entry points, gates and outputs from this section and the stage sheet below. Proposed system; nothing is operating. Drawn by EUTECNIQ. Full-size SVG
Overview

Fifteen detailed steps, filed under the eight Engine stages

Each Engine stage holds one or more detailed steps. Discover enters at Stage 1 (steps 1–2), Qualify & Supply at Stage 2 (step 3) and Develop at Stage 3 or 5 (step 5 or 6). Lawful import (step 4) sits in Stage 2 because samples already need prior notice, and is completed for commercial supply before the scale gate. The channel (supplement, food, cosmetic or drug) is named at the intake screen and confirmed at the route gate, because the first lawful use fixes it. Every stage ends in a written decision to progress, repeat or stop; the four named gates are the decisions that close a block of stages.

The step-by-step table and the detail for each step follow, closed by default: open the fifteen-step detail for the methods, standards, records and stop conditions behind each step.

Three ways into the eight Engine stages, with the fifteen detailed steps and four named gates; safety studies, certification and any drug program would be led by partnersProposed Schematic
The proposed Ingredient Engine with its three ways in: Stage 0 intake screen, then eight stages holding the fifteen detailed steps. Discover enters at Stage 1 (steps 1 and 2), Qualify and Supply at Stage 2 (steps 3 and 4), Develop at Stage 3 (step 5) or Stage 5 (steps 6 and 11). Named gates: the route gate is screened at Stage 0 and confirmed at Stage 8; the identity gate closes Stage 4 (steps 7 and 8); the safety gate closes Stage 6 (steps 9, 10 and 12); the scale gate closes Stage 7. Safety and efficacy studies, third-party validation and any drug development would be partner-led.Engine stageDetailed stepsWay in or named gate0Intake and feasibility screenIntended use named; lawful route and evidence cost screenedAll three ways in starthereRoute gate, first pass1Discover and prioritizeStep 1: Find candidates (in house with partners), Engine Stage 11Find candidatesStep 2: Identify the actives (in house with partners), Engine Stage 12Identify theactivesDiscover enters2Authenticate and qualify the sourceStep 3: Qualify suppliers (in house with partners), Engine Stage 23Qualify suppliersStep 4: Import legally (in house with partners), Engine Stage 24Import legallyQualify & Supply enters3Extract, separate and optimizeStep 5: Make the ingredient (in house (proposed)), Engine Stage 35Make theingredientDevelop enters(process)4Characterize and standardizeStep 7: Validate methods (in house (proposed)), Engine Stage 47Validate methodsStep 8: Screen for unknowns (in house (proposed)), Engine Stage 48Screen forunknownsIdentity gate5Engineer deliveryStep 6: Formulate (in house (proposed)), Engine Stage 56FormulateStep 11: Choose the final format (in house (proposed)), Engine Stage 511Choose the finalformatDevelop enters(delivery)6Establish safety and performanceevidenceStep 9: Safety and efficacy studies (partner-led), Engine Stage 69Safety andefficacy studiesStep 10: Set a safe dose (in house (proposed)), Engine Stage 610Set a safe doseStep 12: Test combinations (in house with partners), Engine Stage 612TestcombinationsSafety gate7Scale, validate and transferTransfer package; commercial import completed (step 4)Scale gate8Commercialize, license, supply orpursue drug developmentStep 13: Third-party validation (partner-led), Engine Stage 813Third-partyvalidationStep 14: Choose markets (in house with partners), Engine Stage 814Choose marketsStep 15: Drug path, if warranted (partner-led), Engine Stage 815Drug path, ifwarrantedRoute gate, confirmedbefore any public stepIntended use named at the intake screen and confirmed at the route gate: the first lawful use fixes supplement or drug status, 21 U.S.C. 321(ff)(3)(B).In house (proposed)In house with partnersPartner-ledNamed gate: proceed, loop back or stopThe proposed Ingredient Engine as a vertical list: each stage with its detailed steps, the three ways in and the four named gatesStage 0 · Intake and feasibility screenAll three ways in start hereIntended use named; lawful route and evidence costscreenedRoute gate, first passStage 1 · Discover and prioritizeDiscover enters1Find candidatesIn house with partners2Identify the activesIn house with partnersStage 2 · Authenticate and qualify the sourceQualify & Supply enters3Qualify suppliersIn house with partners4Import legallyIn house with partnersStage 3 · Extract, separate and optimizeDevelop enters (process)5Make the ingredientIn house (proposed)Stage 4 · Characterize and standardize7Validate methodsIn house (proposed)8Screen for unknownsIn house (proposed)Identity gateStage 5 · Engineer deliveryDevelop enters (delivery)6FormulateIn house (proposed)11Choose the final formatIn house (proposed)Stage 6 · Establish safety and performance evidence9Safety and efficacy studiesPartner-led10Set a safe doseIn house (proposed)12Test combinationsIn house with partnersSafety gateStage 7 · Scale, validate and transferTransfer package; commercial import completed (step4)Scale gateStage 8 · Commercialize, license, supply or pursuedrug development13Third-party validationPartner-led14Choose marketsIn house with partners15Drug path, if warrantedPartner-ledRoute gate, confirmed before any public stepIntended use named at the intake screen and confirmed atthe route gate: the first lawful use fixes supplement ordrug status, 21 U.S.C. 321(ff)(3)(B).
In-house and partner assignments are proposals.Stages restate the Ingredient Engine; ways in, steps and gates restate the track and gate tables above and the step table below. Channel rule: 21 U.S.C. 321(ff)(3)(B).
Text version of the figure
  1. Ways in: Discover (new botanicals, compounds and technologies) enters at Stage 1, Qualify & Supply (ingredients from international manufacturers) at Stage 2, and Develop (an existing ingredient, delivery system or process) at Stage 3 or 5 with its specification. All pass the Stage 0 intake screen first.
  2. Stage 0 · Intake and feasibility screen: intended use named; lawful route and evidence cost screened (route gate, first pass).
  3. Stage 1 · Discover and prioritize: 1 find candidates; 2 identify the actives.
  4. Stage 2 · Authenticate and qualify the source: 3 qualify suppliers; 4 import legally (samples, then commercial lots).
  5. Stage 3 · Extract, separate and optimize: 5 make the ingredient.
  6. Stage 4 · Characterize and standardize: 7 validate methods; 8 screen for unknowns. Identity gate: identity on real lots, content held to a specification, validated methods.
  7. Stage 5 · Engineer delivery: 6 formulate; 11 choose the final format.
  8. Stage 6 · Establish safety and performance evidence: 9 safety and efficacy studies (partner-led), 10 set a safe dose, 12 test combinations. Safety gate: no known hazard at the intended exposure; EDI/ADI ≤ 1.
  9. Stage 7 · Scale, validate and transfer: transfer package; commercial import completed (step 4). Scale gate: commercial lots meet the specification, entry is cleared and the terms are written.
  10. Stage 8 · Commercialize, license, supply or pursue drug development: 13 third-party validation (partner-led), 14 choose markets, 15 drug path if warranted (partner-led). Route gate, confirmed before any public step. Then launch, license or stop.

Reference

The intake screen and all eight Engine stages on one sheet

The question each stage answers, when a program proceeds past its gate, the record it leaves and the change that sends it back to the feasibility screen, as on the Ingredient Engine page. All entries are proposed.

The intake screen and eight Ingredient Engine stages: question, gate criterion, record produced and re-screen trigger
StageQuestionProceeds whenProducesRe-screen if
0 · Intake and the regulatory and economic feasibility screenIs there a lawful route for the intended use, and can its evidence be produced at a cost the product can carry?A lawful route exists for the intended use, and its evidence can be produced at an acceptable cost.A dated screen record that every later gate reads and amendsNo; a change here does not re-run the screen by itself
1 · Discover and prioritizeWhich candidates deserve laboratory time, and on what evidence?The candidate has documented starting evidence, a category hypothesis and a source that can be qualified.Candidate dossier, active-constituent map, draft target product profileNo; a change here does not re-run the screen by itself
2 · Authenticate and qualify the sourceIs the material what the supplier says it is, and can it be supplied consistently and lawfully?Two orthogonal methods agree with an authenticated reference, adulterant screens are negative, and several documented lots are available.Identity passport, supplier qualification file, import fileA new species, plant part, origin or supplier
3 · Extract, separate and optimizeWhich process gets the actives out at a defined composition, with an acceptable residue and cost?The process gives the target composition repeatably at laboratory scale, the mass balance closes and the residue fits the category.Process description, laboratory design space, closed mass balanceA new solvent, concentration or purification step
4 · Characterize and standardizeWhat is in the material, how much does it vary, and can every specification be measured reliably?Every attribute has a fit-for-purpose method, composition falls in a range that can be justified, and contaminants are below the proposed limits.Specification with reasons for each limit, validated methods, certificate-of-analysis formatNo; a change here does not re-run the screen by itself
5 · Engineer deliveryWhich barrier limits the active, and which carrier addresses it in the intended format?The prototype meets its physical and chemical stability targets, and a stated mechanism links the carrier to the identified barrier.Formulation prototype, delivery technology dossierA new carrier, particle size or dosage form
6 · Establish safety and performance evidenceIs the ingredient safe at the intended intake, and does the product do what its design is meant to do?No hazard is known at the intended exposure, EDI/ADI is 1 or less, and the performance target set at stage 5 is met by the kind of evidence the intended claim needs.Safety and exposure assessment, study reports, stability dataA new population, dose or claim
7 · Scale, validate and transferDoes a larger process make on-specification material with its critical parameters known, and can another site repeat it?Consecutive pilot batches meet the specification under a written control strategy, and every release attribute has a validated method.Process development and transfer package, control strategyA change of process, scale or site
8 · Commercialize, license, supply or pursue drug developmentWhich route turns the evidence into value: a client program, a license, supply or a partnered drug program?A customer or partner commits, ownership and data terms are agreed before work starts, and counsel has reviewed freedom to operate.IP and commercialization assessment, supply and quality agreements, or a partnering fileNew claims, a new market or a drug use
The fifteen-step detail Select to show or hide the step table and one section per step group: candidates, suppliers and import, methods, safety, dose, format, combinations, markets and the drug path
Step table

Step by step

Each row is one detailed step: the Engine stage it belongs to, the question it answers, the methods and named standards, the record it would leave, the condition that stops a weak candidate, and who would do the work. Stop conditions are proposed internal criteria unless a rule is cited.

The fifteen proposed steps, each with its Engine stage, question, methods and standards, record, stop condition and who would do the work
StepQuestionMethods and standardsRecordStop ifWho
1 · Find candidatesStage 1Which candidates are worth testing, on what starting evidence?Historical and traditional-system texts, ethnobotanical surveys with local communities, and literature and database reviewCandidate dossier with sources and access statusNo documented starting evidence, the species is threatened without a sustainable source, or access terms cannot be agreedIn house, with field researchers in the provider country
2 · Identify the activesStage 1Which constituents carry the effect?Bioactivity-guided fractionation, dereplication, molecular networking, LC-HRMS and NMRActive-constituent map and draft markersActivity disappears on fractionation or traces to a known toxicantIn house; NMR at partner laboratories in Phase I
3 · Qualify suppliersStage 2Can a supplier deliver the right material, consistently and lawfully?Capacity and cGMP audit, certificate-of-analysis verification and specifications per 21 CFR 111.70. USP <561>, <563>, <565>, ICH Q3C and Q3D as benchmarksSupplier qualification file and approved specificationsLots fail identity or contaminant limits, or the supplier cannot be auditedIn house, with in-country auditors
4 · Import legallyStage 2Can the material enter the United States lawfully?FDA Prior Notice, Foreign Supplier Verification Program, USDA APHIS permits, CITES, and provider-country access and benefit-sharing (Nagoya Protocol)Import file: permits, prior notices, FSVP records, access agreementsA required permit or access agreement is missingIn house, with customs brokers
5 · Make the ingredientStage 3Can the actives be extracted, purified and held to a defined content?Extraction, purification and standardization; EMA extract types (standardized, quantified, other)Process description and ingredient specificationContent cannot be held within a defined range lot to lotIn house (laboratory, then pilot)
6 · FormulateStage 5Does the ingredient work in a stable product?Prototype formulation, compatibility and stability studiesPrototype formula and stability dataThe actives degrade or separate within the intended shelf lifeIn house
7 · Validate methodsStage 4Can every specification be measured reliably?ICH Q2(R2) as the validation framework, AOAC and USP methods where they exist, and 21 CFR 111.75(h)(1)Validated methods with validation reportsA specification has no scientifically valid methodIn house
8 · Screen for unknownsStage 4Is anything present that the specification does not name?Non-targeted LC-HRMS and spectral-library screening for adulterants and unknownsNon-targeted screening reportAn adulterant or unexplained major constituent appearsIn house
9 · Safety and efficacy studiesStage 6Is it safe at the intended intake, and does it do what is claimed?Selected for each ingredient from its known hazards, prior human use, intended intake and regulatory route: in vitro screens, GLP studies (21 CFR Part 58) to OECD 408, 471, 487, 473/474, 414, 416/443 and 451/453, and limited human studiesStudy reports; NDI notification if requiredGenotoxicity, a low NOAEL relative to intake, or no effect in humansPartner GLP laboratories and CROs; in vitro screens in house
10 · Set a safe doseStage 6What daily intake does the evidence support?NOAEL or benchmark dose with safety factors, EDI/ADI, margin of exposure, TTC, and FDA 2005 HED scaling for drugs. An LD50 ranks acute hazard and does not set a human intakeSafety calculation and intake limitEDI/ADI is greater than 1 at the intended doseIn house, on partner data
11 · Choose the final formatStage 5Which delivery format gives the needed exposure?Lipid systems, nanoemulsions, phospholipid complexes, cyclodextrins, solid dispersions, ion pairing; human PK where justifiedDelivery dossier with exposure dataNo format raises exposure, or the format changes the safety caseIn house; human PK with CROs
12 · Test combinationsStage 6Do combinations add, multiply or cancel effects, or interact with drugs?Loewe additivity, Bliss independence, combination index, isobolograms; CYP and transporter interaction screensCombination and interaction reportAntagonism, or a clinically relevant drug interactionIn house in vitro; clinical studies with CROs
13 · Third-party validationStage 8Will an independent body confirm the claims made?Third-party testing and certification, USDA organic (7 CFR Part 205) and non-GMO programsCertificates and audit reportsA claim cannot be certified or substantiatedCertifiers and accredited laboratories
14 · Choose marketsStage 8Where does the ingredient fit, under which rule?Supplements (21 CFR Part 111), foods and beverages (Part 117, GRAS), cosmetics (MoCRA) and new dosage formsMarket-access assessmentThe intended use falls outside every lawful channelIn house, with customers and counsel
15 · Drug path, if warrantedStage 8Should a therapeutic signal become a drug program?21 U.S.C. 321(ff)(3)(B), IND (21 CFR 312), FDA Botanical Drug Development Guidance (2016)Channel decision and partnering fileNo partner, or the supplement channel is already the chosen first useSpin-off, licensee, buyer or CDMO and CRO partners

Rules as cited in the stage sections below; eCFR current to October 21, 2026. Phase I is the proposed laboratory core on the facilities roadmap.

Steps 1–2 · Stage 1

Candidates and their actives

A Discover candidate can start from documented human use (historical and traditional-system texts, ethnobotanical surveys of local people), from the scientific literature, or from a compound or technology already described. Traditional use is not clinical proof. The Develop and Qualify & Supply tracks skip Stage 1 (steps 1 and 2). Kew counted 25,791 documented medicinal plant species in 2020; of 5,411 assessed for extinction risk, 723 (13%) were threatened, so sourcing is screened from the start.

The actives are then traced by fractionating an extract and testing each fraction, with dereplication to drop known compounds early. Detail: discovery and characterization and targeted and non-targeted analysis.

Methods used to find the constituents responsible for an effect
MethodWhat it answersLimit
Bioactivity-guided fractionationWhich fraction keeps the activity, step by stepActivity spread across several constituents can be lost on separation
DereplicationWhether an active fraction holds an already-known compoundOnly as good as the reference spectra and databases
Molecular networking (GNPS)Which constituents are structurally related, from MS/MS spectral similaritySimilar spectra suggest, but do not prove, related structures
LC-HRMSAccurate mass and fragments for each constituentIsomers can share a formula; identity needs a standard or NMR
NMRFull structure of an isolated constituentNeeds milligram amounts of a purified compound

Royal Botanic Gardens, Kew. State of the World's Plants and Fungi 2020, doi:10.34885/172; Wang M, et al. Nat Biotechnol 2016;34:828–837 (GNPS). Related: botanical atlas, heritage.

Steps 3–4 · Stage 2

Suppliers and import

A supplier's certificate of analysis does not establish identity: a supplement manufacturer must verify the identity of every dietary ingredient by at least one test or examination before use. USP chapters and ICH limits written for medicines would serve as benchmarks for specifications, not as legal requirements for supplements. Import adds FDA, USDA and treaty duties, and access to the plant falls under the provider country's law. Buyer duties: FSVP for buyers.

Supplier and import requirements with their rule or benchmark and the record each produces
RequirementRule or benchmarkRecord
Identity, purity, strength, composition and contaminant limits for each component21 CFR 111.70(b)(1)–(3) RegulationComponent specification
At least one identity test or examination of every dietary ingredient before use21 CFR 111.75(a)(1)(i) RegulationLot identity record
Scientifically valid test methods21 CFR 111.75(h)(1) RegulationMethod file
Botanical tests and identificationUSP <561> Articles of Botanical Origin; <563> Identification of Articles of Botanical Origin; <565> Botanical Extracts BenchmarkSpecification references
Elemental impuritiesICH Q3D(R2) oral PDE: lead 5, cadmium 5, inorganic arsenic 15, inorganic mercury 30 µg/day BenchmarkContaminant limits
Residual solventsICH Q3C(R9): benzene 2 ppm (Class 1); hexane 290 ppm and methanol 3,000 ppm (Class 2, Option 1) BenchmarkSolvent limits
Advance notice of imported foodFDA Prior Notice, 21 CFR 1.276–1.285 RegulationPrior Notice confirmations
Foreign supplier verification by the importer21 CFR Part 1, Subpart L; § 1.511 for dietary supplements RegulationFSVP file
Plant material entry and protected speciesUSDA APHIS permits; CITES permits for listed species RegulationPermits
Access and benefit-sharingNagoya Protocol (adopted October 29, 2010; in force October 12, 2014): prior informed consent and mutually agreed terms. The United States is not a Party; the provider country's law applies at the point of access TreatyAccess permit and benefit-sharing agreement

eCFR Title 21, Parts 1 and 111 (current to October 21, 2026); USP Herbal Medicines Compendium, general chapters list; ICH Q3D(R2) (2022), Q3C(R9) (2024); Convention on Biological Diversity, “About the Nagoya Protocol”. Related: quality standards, CFR atlas, contaminants.

Steps 5–8 · Stages 3–5

Ingredient, formulation and methods

Extraction yield and purity are different measures, and the extract type decides how the content is controlled. The European Medicines Agency's herbal committee distinguishes three types. Formulation then has to keep the actives intact through shelf life, and every specification needs a validated method. Detail: extraction, purification and standardization, emulsions and colloids, method development.

EMA herbal extract types and how each is defined
Extract typeDefinition (quoted)What is controlled
Standardized“adjusted within an acceptable tolerance to a given content of constituents with known therapeutic activity”Content of the active constituents
Quantified“adjusted to a defined range of constituents (active markers)”A range of marker constituents
Other“essentially defined by their production process (state of the herbal drug to be extracted, solvent, extraction conditions) and their specifications”The process and the specification

EMA/HMPC/186645/2008, Reflection paper on the level of purification of extracts to be considered as herbal preparations (adopted September 16, 2010), section 6.

Methods would be validated with ICH Q2(R2), which FDA issued as final guidance in March 2024 for registration applications; for supplements the legal test is a scientifically valid method (21 CFR 111.75(h)(1)). A targeted method finds only what it looks for, so non-targeted screening would look for adulterants and unknowns. Separately, a widely cited 2013 DNA-barcoding survey of herbal products was retracted in 2024 after an investigation found evidence of data fabrication. Detail: targeted and non-targeted analysis, instruments.

FDA, Q2(R2) Validation of Analytical Procedures, final guidance, March 2024; 21 CFR 111.75(h); BMC Medicine retraction notice, July 4, 2024.

Step 9 · Stage 6

Safety and efficacy studies

Part 58 (good laboratory practice) governs nonclinical studies supporting INDs, NDAs, food additive petitions and GRAS submissions; NDI notifications are not on its list, and FDA's 2026 NDI guidance does not mention GLP. EUTECNIQ would still commission definitive studies from GLP partner laboratories so the data could support a later drug or food filing. Detail: toxicology.

Two in vitro genotoxicity tests and a 90-day study cost about €140,000 (the in vivo test that completes the three-study battery is not priced in the source); multigeneration reproduction and carcinogenicity studies cost three to seven times as much as the 90-day studyThird-party estimate
Price of single GLP studies quoted by EU contract laboratories, 2010-2018, in euros: OECD 471 Bacterial reverse mutation (Ames) €3,800; OECD 487 In vitro micronucleus €8,500; OECD 473 In vitro chromosomal aberration €13,200; OECD 475 In vivo bone-marrow chromosomal aberration €62,500; OECD 414 Prenatal developmental toxicity, rat €77,700; OECD 408 90-day oral toxicity, rat €105,600; OECD 416 Two-generation reproduction €328,000; OECD 443 Extended one-generation reproduction €566,000; OECD 451 Carcinogenicity €700,000. The 90-day study ranged from €87,200 to €161,200.€0€250k€500k€750kPrice per study, euros (EU quotes, 2010–2018)OECD 471Bacterial reverse mutation (Ames)OECD 471 Bacterial reverse mutation (Ames): €3,800€3,800OECD 487In vitro micronucleusOECD 487 In vitro micronucleus: €8,500€8,500OECD 473In vitro chromosomal aberrationOECD 473 In vitro chromosomal aberration: €13,200€13,200OECD 475In vivo bone-marrow chromosomalaberrationOECD 475 In vivo bone-marrow chromosomal aberration: €62,500€62,500OECD 414Prenatal developmental toxicity, ratOECD 414 Prenatal developmental toxicity, rat: €77,700€77,700OECD 40890-day oral toxicity, ratOECD 408 90-day oral toxicity, rat: €105,600€105,600 (range €87,200–€161,200)OECD 416Two-generation reproductionOECD 416 Two-generation reproduction: €328,000€328,000OECD 443Extended one-generation reproductionOECD 443 Extended one-generation reproduction: €566,000€566,000OECD 451CarcinogenicityOECD 451 Carcinogenicity: €700,000€700,000Core of an NDI package in FDA's 2026 guidance (genotoxicity and a 90-day study)Further studies, by use and evidence gapsPrice of single GLP studies quoted by EU contract laboratories, 2010-2018Price per study, euros (EU quotes, 2010–2018)OECD 471 · Bacterial reverse mutation (Ames)€3,800OECD 487 · In vitro micronucleus€8,500OECD 473 · In vitro chromosomal aberration€13,200OECD 475 · In vivo bone-marrow chromosomalaberration€62,500OECD 414 · Prenatal developmental toxicity, rat€77,700OECD 408 · 90-day oral toxicity, rat€105,600 (range €87,200–€161,200)OECD 416 · Two-generation reproduction€328,000OECD 443 · Extended one-generation reproduction€566,000OECD 451 · Carcinogenicity€700,000Core NDI packageFurther studies
EU contract-laboratory quotes from 2010–2018, probably below 2026 prices; not U.S. prices and not EUTECNIQ quotes. OECD 474 (in vivo micronucleus) is not priced in the source; OECD 475 is shown. Core total computed here: €3,800 + €8,500 + €105,600 + about €10,000 pre-test + about €12,000 dose analytics = €139,900.Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. ALTEX 2018;35(3):275–305, Table 3, doi:10.14573/altex.1807041.
OECD test guidelines listed here, what each detects and its duration
OECD guidelineDetectsDuration and size, where citedRole in an NDI notification
471 AmesGene mutations in bacteria—Both FDA batteries
487 or 473Chromosome damage in mammalian cells in vitro—Both batteries (FDA prefers the mouse lymphoma tk assay)
474Chromosome damage in vivo (erythrocyte micronucleus)—Third study of the three-study battery
408Target organs and a NOAEL after repeated dosing90 days of oral dosingBasis for EDI/ADI and margin of safety
414, 416, 443Developmental and reproductive effects—Reproductive study when labeled for pregnancy, lactation or young children
451, 453Tumors after lifetime exposureOECD 451: normally 24 months in rodents, at least 50 animals per sex per groupNot in the standard list. Recommended if a genetic toxicity test is positive (section VII.6), and routine in drug and food-additive programs

21 CFR 58.1 and 58.3(e) (eCFR, current to October 21, 2026); FDA, NDI Notifications and Related Issues; Identity and Safety Information About the NDI, final guidance, October 2026, sections VII.1 and IX; OECD Test No. 451 (2018). A dash means the guideline's duration is not given here.

Human studies follow the animal data. A study designed to test whether a supplement can diagnose, cure, mitigate, treat or prevent a disease needs an IND under 21 CFR Part 312. A new ingredient then needs an NDI notification at least 75 days before marketing; FDA's answer is “acknowledged without objection” (see what FDA’s reply means). Detail: clinical research, NDI notifications, GRAS.

NDI notifications acknowledged without objection by fiscal year
PeriodAcknowledged without objection
All substantive responses to December 2020 (1,078)36.5%
FY2018 (17 of 38)44.7%
FY2019 (19 of 40)47.5%
FY2022 (30 of 42)71%
FY2023 (27 of 44)61%

FDA data obtained under FOIA, as reported by SupplySide Supplement Journal; counts differ by definition and are not FDA publications. FDA, Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013, section VI.D.1; 21 CFR 190.6.

Step 10 · Stage 6

From NOAEL to a safe dose

An LD50 ranks acute hazard; it does not set a daily intake, and the OECD deleted the classical LD50 test (TG 401) on December 17, 2002. A safe intake starts from a NOAEL. For drugs, FDA's 2005 guidance converts it by body surface area and divides by 10; for a new dietary ingredient, FDA's NDI guidance divides the mg/kg NOAEL by combined safety factors of about 100, 1,000 or 2,000. Detail: risk assessment.

The same kind of animal result leads to a starting dose for a drug and to an acceptable daily intake for an NDIFDA guidance
One kind of animal result, two frameworks, using FDA's own worked examples. Drug: rat NOAEL 50 mg/kg divided by 6.2 gives a human equivalent dose of about 8 mg/kg, divided by a default safety factor of 10 gives a starting dose of about 0.8 mg/kg. New dietary ingredient: rat NOAEL 3,000 mg/kg/day from a single 90-day study divided by 2,000 gives an ADI of 1.5 mg/kg/day; an intake of 1 mg/day for a 70 kg adult is 0.014 mg/kg/day, an EDI/ADI ratio of 0.01.Drug: maximum recommended starting doseFDA 2005 guidance, first-in-human trials in adult healthy volunteers50 mg/kgRat NOAEL (FDA conversion example)HED ≈ 8 mg/kg÷ 6.2 (rat to human, body surface area)MRSD ≈ 0.8 mg/kg÷ 10 (default safety factor)Supplement: acceptable daily intake for an NDIFDA NDI guidance, October 2026, section IX.5–63,000 mg/kg/dayRat NOAEL, single 90-day study, no effect at the top doseADI = 1.5 mg/kg/day÷ 2,000 (10 × 20 × 10)0.014 mg/kg/dayEDI: 1 mg/day ÷ 70 kg0.01 (≤ 1 supports safety)EDI ÷ ADIOne kind of animal result, two frameworks, using FDA's own worked examplesDrug: maximum recommended starting doseFDA 2005 guidance, first-in-human, adult healthy volunteers50 mg/kgRat NOAEL (FDA conversion example)HED ≈ 8 mg/kg÷ 6.2 (rat to human, body surface area)MRSD ≈ 0.8 mg/kg÷ 10 (default safety factor)Supplement: acceptable daily intake for an NDIFDA NDI guidance, October 2026, section IX.5–63,000 mg/kg/dayRat NOAEL, single 90-day study, no effect at the topdoseADI = 1.5 mg/kg/day÷ 2,000 (10 × 20 × 10)0.014 mg/kg/dayEDI: 1 mg/day ÷ 70 kg0.01 (≤ 1 supports safety)EDI ÷ ADI
FDA's own worked examples, reproduced; not values for any ingredient. The NDI calculation applies safety factors to the mg/kg NOAEL without a body-surface-area conversion.FDA, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, July 2005, Table 1; FDA NDI guidance, October 2026, section IX.5–6.
Toxicological reference points and how each is used
Reference pointValue or ruleUse
Combined safety factor, NDI100 for a chronic study, 1,000 from rodent and non-rodent 90-day studies, 2,000 from one rodent 90-day studyADI = NOAEL ÷ factor; EDI/ADI ≤ 1 supports safety
Human equivalent dose, drugsRat mg/kg ÷ 6.2 (Km 6 vs 37 for humans); default safety factor 10First-in-human starting dose
Margin of exposure≥ 10,000 from a BMDL10 in animals: low concern for a genotoxic carcinogenImpurities that are genotoxic and carcinogenic
Threshold of toxicological concern0.0025 (DNA-reactive), 1.5 (Cramer III), 9 (II), 30 (I) µg/kg bw per dayScreening of minor constituents without toxicity data

FDA NDI guidance (October 2026), section IX.5–6; FDA (2005), Table 1; EFSA Scientific Committee, EFSA Journal 2012;10(3):2578; EFSA Scientific Committee, EFSA Journal 2019;17(6):5708; OECD, Test No. 401 publication page.

Step 11 · Stage 5

Delivery format and brain exposure

A delivery format can raise dissolution or absorption, but a stable nanoemulsion is a formulation result, not proof of bioavailability; only exposure measured in people shows that. Brain entry is limited further by efflux transporters on brain capillaries. A message that a product “crosses the blood–brain barrier to treat” a disease states a disease use, which makes it a drug. Detail: bioavailability design, ADME and PBPK.

Delivery approaches, their principle and what must be measured to support a claim
ApproachPrincipleEvidence needed before a claim
Lipid-based systemsKeep a lipophilic compound dissolved through digestion; very lipophilic compounds may reach lymphHuman PK against the plain extract
NanoemulsionsSmall oil droplets raise the dispersed surfaceDroplet size and stability, then human PK
Phospholipid complexesAssociation with phospholipids changes solubility and membrane passageComplex characterization, then human PK
Cyclodextrin inclusion complexesA host molecule holds the compound in its cavity and raises apparent solubilityComplexation data, then human PK
Amorphous solid dispersionsA polymer holds the compound in a higher-energy, faster-dissolving formPhysical stability on storage, then human PK
Ion pairing and ion exchangeA counter-ion or resin changes charge, lipophilicity or releaseDissociation behavior, then human PK
Facts about brain entry and the claim rule
PointEvidence
CNS MPO scoreSix properties (ClogP, ClogD7.4, MW, TPSA, HBD, most basic pKa), 0–6; 74% of 119 marketed CNS drugs scored ≥ 4, against 60% of Pfizer CNS candidates
Efflux at the barrierP-gp and BCRP sit on the luminal membrane of brain capillary endothelium and pump substrates back into blood
Claim ruleArticles intended for the diagnosis, cure, mitigation, treatment or prevention of disease are drugs (21 U.S.C. 321(g)(1)); supplements may carry structure/function statements with the 21 CFR 101.93 disclaimer

Wager TT, et al. ACS Chem Neurosci 2010;1:435–449; Porter CJH, Trevaskis NL, Charman WN. Nat Rev Drug Discov 2007;6:231–248 (lymphatic transport); Giacomini KM, et al. Nat Rev Drug Discov 2010;9:215–236; 21 U.S.C. 321(g)(1), 343(r)(6); 21 CFR 101.93. Related: delivery, dosage forms.

Step 12 · Stage 6

Combinations and interactions

“Synergy” is a measured result against a stated reference model, and the two common models can disagree: a combination can be synergistic under one and antagonistic under the other. Combinations with vitamins, minerals or other botanicals would be tested against both. Botanical–drug interactions belong in the same stage: 14 days of a St. John's wort extract (41 mg/day hyperforin) cut oral midazolam AUC by 79.4%. Detail: combination science; ingredient pairs: documented interactions in Supplements A–Z.

Reference models for testing combinations
ModelExpected effect without interactionRead-out
Loewe additivityEach agent behaves as a dilution of the other; dA/DA + dB/DB = 1Isobologram: points below the additive line indicate synergy
Combination index (Chou–Talalay)CI = 1 additiveCI < 1 synergism; CI > 1 antagonism
Bliss independenceAgents act independently; expected fractional effect EA + EB − EA·EB (the product of the fractions left unaffected gives the same result)Observed minus expected at each dose pair

Tallarida RJ. J Pharmacol Exp Ther 2006;319:1–7; Chou T-C. Cancer Res 2010;70:440–446; Tang J, Wennerberg K, Aittokallio T. Front Pharmacol 2015;6:181; Mueller SC, et al. Eur J Clin Pharmacol 2006;62:29–36 (six parallel groups, 42 healthy men in total). D: dose of each agent alone giving the chosen effect; d: its dose in the mixture giving the same effect.

Steps 13–14 · Stage 8

Certification and markets

Some label terms are defined by regulation and some only by private programs or by the seller. Each market has its own rule set, and the dosage form can move a product out of the supplement category. Detail: clean label and the applications pages.

Label terms, who defines them and the rule
TermDefined byRule
“100 percent organic”, “organic”, “made with organic”USDA National Organic Program100%, at least 95% and at least 70% organic ingredients, excluding water and salt (7 CFR 205.301)
Bioengineered disclosureUSDA, 7 CFR Part 66Exempt if no ingredient intentionally contains a bioengineered substance, allowing up to 5% inadvertent presence per ingredient (§ 66.5(c))
“Non-GMO”Private programsNot defined in Title 21 CFR
“Clean label”The seller or retailerThe phrase appears in no section of Title 21 CFR (eCFR search, October 28, 2026)
Markets, the main U.S. rule for each, and the page with detail
MarketMain U.S. ruleDetail
Dietary supplements“Intended for ingestion” (21 U.S.C. 321(ff)); manufacturing under 21 CFR Part 111Dietary supplements
Foods and beverages21 CFR Part 117; GRAS or food-additive status (mandatory GRAS notification proposed August 11, 2026)Foods and beverages
CosmeticsMoCRA: facility registration, product listing, serious adverse events reported within 15 business daysCosmetics and personal care
New formatsFDA: sublingual products “are not dietary supplements and are not foods” (warning letter, February 5, 2019)Dosage forms

eCFR Title 7, Parts 66 and 205 (current to October 21, 2026); eCFR full-text search of Title 21 for “clean label” (0 results, October 28, 2026); 21 U.S.C. 321(ff); Federal Register, August 11, 2026 (91 FR 51834, proposed rule); FDA cosmetics registration and listing page; FDA warning letter to DK Vitamins, February 5, 2019.

Step 15 · Stage 8

Supplement or drug

An article that has been approved as a new drug, or investigated as one with substantial clinical investigations instituted and made public, is excluded from the supplement definition unless it was first marketed as a supplement or food. The first lawful use therefore decides the channel, which is why every track names its intended use at the start and the route gate confirms it before any public step. The drug path is long: FDA lists four botanical drugs approved under an NDA or BLA, from 2006 to 2023.

Intended use decides the channel, and the first public step makes the choice hard to reverseRegulation Proposed execution
Supplement or drug: if the intended use is not a disease use, the supplement or food channel applies, with structure/function statements, an NDI notification for a new ingredient, and marketing first as a supplement keeping that channel open. If it is, the product is a drug: an IND, botanical drug development and an NDA or BLA; once substantial clinical investigations are made public first, the article cannot become a supplement. FDA lists four botanical drugs approved under an NDA or BLA, 2006–2023.A candidate with a credible therapeutic signal (step 2, or safety and effectwork before the safety gate)Intended use: diagnose, cure,mitigate, treat or prevent a disease?NoYesSupplement or food channelStructure/function statements only: FDA notified within 30 days, labeldisclaimer (21 U.S.C. 343(r)(6); 21 CFR 101.93)New ingredient?NDI notification at least 75 days before marketing (21 CFR 190.6); FDAresponse is 'acknowledged without objection', not approvalMarketed first as a supplement or foodThe 321(ff)(3)(B) exception keeps the supplement channel open if adrug is developed laterDrug channelA product intended for disease use is a drug (21 U.S.C. 321(g)(1)); adisease-endpoint study needs an IND (21 CFR 312)Botanical drug developmentFDA Botanical Drug Development Guidance (December 2016); NDA orBLA; 5-year NCE exclusivity exists only for approved drugsInvestigated first as a drugOnce substantial clinical investigations are instituted and made public,the article is excluded from the supplement definitionDrug path: FDA lists 4 botanical drugs approved under an NDA orBLA, 2006–2023Executed through a spin-off, licensing, sale, or partnership withCDMOs and CROs (proposed)Supplement or drug: the intended-use question and what follows on each sideA candidate with a credible therapeutic signal (step2, or safety and effect work before the safety gate)Intended use: diagnose, cure, mitigate, treat orprevent a disease?No: supplement or foodSupplement or food channelStructure/function statements only: FDA notified within30 days, label disclaimer (21 U.S.C. 343(r)(6); 21 CFR101.93)New ingredient?NDI notification at least 75 days before marketing (21CFR 190.6); FDA response is 'acknowledged withoutobjection', not approvalMarketed first as a supplement or foodThe 321(ff)(3)(B) exception keeps the supplementchannel open if a drug is developed laterYes: drugDrug channelA product intended for disease use is a drug (21 U.S.C.321(g)(1)); a disease-endpoint study needs an IND (21CFR 312)Botanical drug developmentFDA Botanical Drug Development Guidance (December2016); NDA or BLA; 5-year NCE exclusivity exists onlyfor approved drugsInvestigated first as a drugOnce substantial clinical investigations are institutedand made public, the article is excluded from thesupplement definitionDrug path: FDA lists 4 botanical drugs approvedunder an NDA or BLA, 2006–2023Executed through a spin-off, licensing, sale, orpartnership with CDMOs and CROs (proposed)
Simplified; the statutory text and counsel decide individual cases.21 U.S.C. 321(g)(1), 321(ff)(3)(B), 343(r)(6); 21 CFR 101.93, 190.6, Part 312; FDA CDER, “What is a Botanical Drug?” (updated September 3, 2026); FDA authors, Ther Innov Regul Sci 2025 (254 oncology + 485 non-oncology botanical INDs).

A naturally occurring constituent is not patent-eligible merely because it has been isolated (product-of-nature exception); markedly different compositions, processes, formulations and methods of use can be. Five-year new-chemical-entity exclusivity exists only for approved drugs, and supplements have no data exclusivity. A drug program would therefore go to a partner with drug development capacity.

Proposed ways to carry a drug candidate forward
OptionWhat would transferWhat EUTECNIQ would keep
Spin-offThe candidate and its data, into a separately financed companyA stake and service work
LicenseRights to patents on compositions, processes or usesOwnership, with license income
SaleThe program outrightNone after closing
Partnership with CDMOs and CROsManufacturing under drug GMP and clinical trial workProgram control

Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013); Mayo v. Prometheus, 566 U.S. 66 (2012); FDA, Frequently Asked Questions on Patents and Exclusivity (“Exclusivity attaches upon approval of a drug product”). Options are proposals. Related: pharmaceutical partnerships, commercialization and licensing, legal status.

EUTECNIQ Proposed

Where EUTECNIQ would work

EUTECNIQ would run steps 1 to 8 and the calculations of steps 10 to 12 in its own laboratory, and would place GLP studies, clinical trials, certification and any drug program with qualified partners. In the Qualify & Supply track, qualified external laboratories would run identity, contaminant and stability testing at first. Every gate decision and its record would stay in one file. None of this exists yet.

Related pages: Development pathway · How EUTECNIQ differs · Facilities and roadmap · Digital lab · Regulatory

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]